The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The p53-binding site of MDM2 holds great promise as a target for therapeutic intervention in MDM2-amplified p53 wild-type forms of cancer. Despite the extensive validation of this strategy, there are relatively few crystallographically determined co-complex structures for small-molecular inhibitors of the MDM2-p53 interaction available in the PDB. Here, a surface-entropy reduction mutant of the N-terminal domain of MDM2 that has been designed to enhance crystallogenesis is presented. This mutant has been validated by comparative ligand-binding studies using differential scanning fluorimetry and fluorescence polarization anisotropy and by cocrystallization with a peptide derived from p53. Using this mutant, the cocrystal structure of MDM2 with the benchmark inhibitor Nutlin-3a has been determined, revealing subtle differences from the previously described co-complex of MDM2 with Nutlin-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×
“All data were indexed and integrated using the XDS package (Kabsch, 2010) and were further processed using the CCP4 suite (Winn et al., 2011).”
MethodLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“Introduction The transcription factor p53 is the major tumour suppressor of the cell and plays a central role in the regulation of many cellular mechanisms such as apoptosis, DNA repair, angiogenesis, survival and senescence (Lane, 1992; Vogelstein et al., 2000; Fridman & Lowe, 2003).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 20×
“…intense interest in MDM2 as a target for anticancer drug discovery, only ten small-molecule cocrystal structures have been deposited in the PDB (Vassilev et al., 2004; Ding et al., 2005; Grasberger et al., 2005; Allen et al., 2009; Popowicz et al., 2010; Furet et al., 2012; Graves et al.,…”
BackgroundMethodInfluentialMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Finally, MDM2, which has E3 ligase activity, targets p53 for proteasomal degradation by ubiquitylation (Haupt et al., 1997; Honda et al., 1997; Wade et al., 2010).”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 5×
“The crystal structure of MDM2 in complex with p53 (residues 15–29) shows that the interaction is largely mediated by three key residues of p53, namely Phe19, Trp23 and Leu26, and the binding surface on MDM2 is well defined (Kussie et al., 1996).”
BackgroundMethodInfluentialOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“Finally, MDM2, which has E3 ligase activity, targets p53 for proteasomal degradation by ubiquitylation (Haupt et al., 1997; Honda et al., 1997; Wade et al., 2010).”
BackgroundAmplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · cited 1×
“Introduction The transcription factor p53 is the major tumour suppressor of the cell and plays a central role in the regulation of many cellular mechanisms such as apoptosis, DNA repair, angiogenesis, survival and senescence (Lane, 1992; Vogelstein et al., 2000; Fridman & Lowe, 2003).”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“The p53 gene is altered in 50% of cancers and the function of p53 is down-regulated in cancers where the wild-type protein is retained (Hainaut & Hollstein, 2000; Brown et al., 2009).”
BackgroundStructure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · cited 2×
“…in MDM2 as a target for anticancer drug discovery, only ten small-molecule cocrystal structures have been deposited in the PDB (Vassilev et al., 2004; Ding et al., 2005; Grasberger et al., 2005; Allen et al., 2009; Popowicz et al., 2010; Furet et al., 2012; Graves et al., 2012; Rew et al., 2012).”
Background
Cited by
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 89
Discovering small-molecule senolytics with deep neural networks
Wong, F., Omori, S., Donghia, N. M., Zheng, E. J., & Collins, J. J. (2023) · Nature Aging · doi:10.1038/s43587-023-00415-z · Cited by 82
Bolz, S. N., Schake, P., Stitz, C., & Schroeder, M. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2557599 · Cited by 7
Metadata
- Authors
- Anil, B., Riedinger, C., Endicott, J. A., & Noble, M. E. M.
- Venue
- Acta Crystallographica Section D Biological Crystallography
- Published
- 2013-07-13
- Volume
- 69
- Issue
- 8
- Pages
- 1358-1366
- ISSN
- 0907-4449 (ISSN-L)
- 1399-0047
- OpenAlex
- W2003768436
- Cited by
- 94
- References
- 13
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. https://app.cochat.ai/papers/10.1107/s0907444913004459
- The paper
- Anil, B., Riedinger, C., Endicott, J. A., & Noble, M. E. M. (2013). The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallographica Section D Biological Crystallography. https://doi.org/10.1107/s0907444913004459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.